Epstein-Barr virus (EBV) is associated with several human malignancies including Burkitt's lymphoma (BL),
Introduction
A fundamental question in infectious disease is to understand the mechanisms by which viral stimuli regulate the expression of cellular genes, even more in the case if the viral infection is an important cofactor in the transformation of the infected cells. Epstein-Barr virus (EBV), a unique ␥-Herpesvirus, is the cause of infectious mononucleosis and is detected in a number of tumours including Burkitt's lymphoma (BL), Hodgkin's disease (HD) and nasopharyngeal carcinomas (NPC). EBV naturally infects human B lymphocytes and possibly epithelia cells (for review see Rickinson and Kieff 1 ). The EBV latent membrane protein-1 (LMP1) is a major component in the process of B cell immortalisation and transformation. 2, 3 LMP1 induces tumours in LMP1 transgenic mice. 4 It has been shown that LMP1 induces phenotypic changes of infected cells. It activates the NFB, c-jun-N-terminal-kinase (JNK), Jak/STAT and p38/SAPK2 pathways and influences cellular genes like CD40 or ICAM1/CD54. 2, [5] [6] [7] [8] [9] The essential signalling regions of LMP1 are six hydrophobic transmembrane domains that enable ligand independent aggregation in the plasma membrane and the carboxyterminal region (CCR) that alters cell growth and mediates cellular gene activation. This activation is per-mitted through two major effector domains: the Cterminal activation regions (CTAR) 1 and 2.
3,6,10,11 CTAR1 (amino acids 185-211) mediates the initial induction of lymphocyte transformation, activation of NFB and interacts with tumour necrosis factor receptor-associated factors (TRAFs). [12] [13] [14] CTAR2 (amino acids 374-386) is critical for long-term growth of lymphoblastoid cell lines, interacts with the TNF receptor-associated death domain protein (TRADD) and is also important for NFB, p38/SAPK2 and JNK activation. 6, 10, 13, [15] [16] [17] More recently, a region being involved in STAT1 activation has been named as a third activating region. 8 LMP1 is expressed in most malignancies associated with EBV infection, including Hodgkin's disease and nasopharyngeal carcinomas. 1 It has been suggested that LMP1 is a major regulator of many cytokines and cytokine receptors which are regularly detected in EBVpositive Hodgkin's lymphoma and non-Hodgkin's lymphomas. 9, 18, 19 Recently, we and others have shown that EBV-positive Burkitt's lymphoma cell lines usually express IL-6, IL-8, IL-10, TNF-␣ and TNF-␤, indicating that LMP1 may influence cytokine expression. 9, 18, [20] [21] [22] LMP1-mediated activation of the NFB pathway is responsible for enhanced expression of a number of surface antigens like CD54/ICAM-1 and CD40. 17, 23, 24 The inducible IL-2 receptor ␣-chain (CD25) has been described to be regulated through NFB in several cell types. 25, 26 Thus, LMP1 could be an activator of CD25. Furthermore, studies have shown that in the majority of Hodgkin's disease cases, Hodgkin-Reed Sternberg (H-RS) cells express CD25. 27, 28 Approximately 40% of cases of
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Hodgkin's disease are associated with EBV infection. Figure 2a representative Western blot for LMP1 expression in BL2, BL41 and L428 cells is depicted. As shown recently, levels of LMP1 protein in transfected cells were comparable to those in an EBV-superinfected BL cell line (BL41 B95-8). 9 Directly after magnetic enrich- ment LMP1 and vector control-transfected cells were assayed for surface antigen expression. Figure 2b shows a representative flow cytometry analysis of LMP1 and vector-control transfected BL2 and L428 cells. Cells were stained with ␣-CD25 PE and ␣-CD54/ICAM1 FITC antibody. CD54 is known to be activated by LMP1 in several cells and thus served as an internal control for LMP1 effects. The dot blot analysis clearly shows LMP1 activated CD25 and CD54-expression in LMP1 transfected cells (Figure 2b ). LMP1 expressing cells were characterized by an increased number of CD25 expressing cells as well as a higher expression level of CD25-positive cells. Higher CD25 expression and CD54 level correlated in BL2 and L428 cells. 
2). Also in
Jurkat T cells CD25 levels were slightly higher than in the vector-control transfected counterparts (data not shown).
The C-terminal activation region two (CTAR2) of LMP1 is the major domain involved in CD25 activation
Previous studies have shown that the potential of LMP1 to activate cellular signalling cascades is mediated through the two main effector regions CTAR1 and CTAR2. A LMP1 mutant with a deletion from amino acid 187 to 351 that lacks the CTAR1, retained about 60-80% of NFB and JNK activation potential of full length LMP1 in 293 or Jurkat T cells. A LMP1 deletion mutant expressing only the CTAR1 by deletion of amino acids 232 to 386 is still capable to activate NFB or other signalling cascades. To test whether CTAR1 or CTAR2 of LMP1 are involved in CD25 activation, LMP1 derivatives lacking amino acids 187 to 351 (LMP1 ⌬(187-351)) or 232 to 386 (LMP1 ⌬(232-386)) were analyzed in three different cell lines. Lymphoma cells were transiently transfected with different LMP1 derivatives or vector control and enriched after transfection. CD25 expression was determined by a Data were acquired directly after magnetic separation. The data are presented as mean channel numbers for fluorescence intensity (MFI). MFI was calculated after subtraction of isotype mean fluorescence using the Cellquest software. The mean values ± s.e.m. are shown (n = 5-10).
flow cytometry directly after magnetic enrichment. Equal expression of LMP1 mutants fused to a FLAG-epitope at the N-terminus was confirmed by Western blot analysis as described previously (data not shown). 9 A schematic presentation of the LMP1 mutants used in this study is depicted in Figure 3a . Figure 3b shows a representative FACS analysis of transfected BL2 cells. As illustrated in Figure 3b , 'wild-type' LMP1 caused an increase from 54.6 to 80.3% of CD25-positive BL2 cells. LMP1 ⌬(187-351) mediated a partial CD25 activation (74.4% CD25-positive cells). When the LMP1 mutant containing only the CTAR1 (LMP1 ⌬(232-386) was transfected in BL2 cells, CD25 expression was nearly at vector control level (55.8% CD25-positive cells). Figure 3c summarizes the CD25 expression data obtained from different transfection assays with BL2, BL41 and L428 cells. The data are presented as the mean values of at least five experiments ± s.e.m. CD25 surface expression of LMP1 transfected cells was set as 100%. The LMP1 mutant LMP1 ⌬(187-351) was sufficient to mediate approximately 50-60% of CD25 activation compared to 'wildtype' LMP1 in BL2, BL41 and L428 cells. When the LMP1 mutant containing only the CTAR1 (LMP1 ⌬(233-386) was transfected in BL cells CD25 activation was reduced to 8-10% compared to 'wild-type' LMP1. In L428 cells 27% of activation was detected. In addition LMP1 mutants were analyzed where the CTAR1 or CTAR2 (LMP1 CTAR1mut, LMP1 CTAR2mut) or both regions (LMP1 CTAR1/CTAR2mut) were non-functional because of amino acid substitutions (Figure 3d) . 31 As depicted in Figure 3d , there were no significant differences between the CD25 activation capacity of LMP1 ⌬(187-351) and the LMP1 CTAR1mut construct. The same results were found when LMP1 ⌬(232-386) was compared with the correspondent LMP1 CTAR2mut construct. Both LMP1 mutants showed only 10% activity compared to 'wildtype' LMP1. A LMP1 derivative that contained a mutated CTAR1 and 2 was unable to mediate CD25 expression or activation of CD40, CD54 or interleukin-10 (unpublished own observation). Thus, CTAR1 and 2 are necessary and sufficient to activate CD25, whereas the region between CTAR1 and 2 alone is unable to mediate CD25 gene expression.
CD25 activation by LMP1 involves the NFB pathway
The results obtained with the used LMP1 mutants suggest that the NFB pathway may be involved in the regulation of CD25 gene activation. As reported by several groups CTAR1 and CTAR2 can separately activate cellular pathways. However, it has been reported by us and other groups that the conformation of the C-terminus of LMP1 might influence gene expression of a target gene like CD54 or interleukin-10. 9, 31 In contrast to NFB activation, LMP1 mutants ⌬(187-351) and ⌬(232-386) are unable to mediate interleukin-10 expression in BL2 cells, suggesting that IL-10 regulation involves cellular pathways different from NFB. 9 Furthermore, recent published data suggest that a new functional c-terminal region (CTAR3) of LMP1 located between CTAR1 and 2 may activate cellular pathways. 8 In order to investigate whether LMP1-directed NFB activation is associated with CD25 enhancement, activation of this cellular pathway was analyzed using a NFB-dependent reporter gene assay. 9, 10 Furthermore, reporter gene activation of different LMP1 mutants was The data were the mean (± s.e.m.) of at least five independent experiments. *P Ͻ 0.0001, **P = 0.01, ***P = 0.015 as compared with fulllength LMP1. (d) BL2 cells were transfected with pSG5, pSG5-FLAG-LMP1, pSG5-FLAG-LMP1 ⌬(187-351), pSG5-FLAG-LMP1 ⌬(232-386), pSG5-FLAG-LMP1 CTAR1mut, pSG5-FLAG-LMP1 CTAR2mut, pSG5-FLAG-LMP1 CTAR1/2mut and analyzed as described above. *P Ͻ 0.0001 as compared with full-length LMP1.
compared with the ability of these mutants to enhance CD25 expression. BL2 cells were transiently transfected with LMP1 or vector-control and activation of NFB was measured by cotransfection of a NFB-regulated luciferase reporter plasmid. As shown in Figure 4a LMP1 expression resulted in a six-fold reporter gene activation in BL2 cells. CTAR1 mutated LMP1 variants showed an approximately 60% activation capacity, while CTAR2-deficient mutants were able to mediate 10% activation compared to 'wild-type' LMP1. As already found for CD25 expression, the LMP1 mutant without functional CTAR1 and 2 did not activate the NFB reporter gene. Thus, CD25 activation by CTAR1 or CTAR2 seems to mimick the capacity of these LMP1 regions to activate NFB. 5, 6, 13, 17 To further investigate the role of NFB in CD25 regulation, the NFB pathway was specifically inhibited using a mutated IB-␣ (MAD3/IB-␣ S32AS36A). BL2 cells were cotransfected with 2 g pSG5-LMP1, 12 g IB-␣ S32AS36A or empty vector (pCDNA) and 7 g pMACS4.1. 24-h after transfection cells were enriched by magnetic separation and CD25 expression was investigated. As depicted in Figure 4b coexpression of LMP1 and constitutive repressive IB-␣ S32AS36A led to an inhibition of CD25 expression from 15.8% to 3.3% positive cells. Expression of IB-␣ S32AS36A did not affect basal CD25 surface level. Under these conditions, IB-␣ S32AS36A did not influence LMP1 levels and LMP1-mediated IL-10 expression but strongly inhibits TNF-␣ expression. 9 Thus, NFB activation is a major mediator of LMP1-induced CD25 expression.
LMP1 mediates activation of surface antigens coregulated by NFB in the IB-␣ defective cell line L428
Hodgkin-derived cell lines like L428 are characterized by deregulated NFB and Jak/STAT pathways which are essential for proliferation and survival of H-RS cells. [32] [33] [34] Inhibition of NF by constitutive repressive IB-␣ is associated with apoptosis of HD derived cell lines. 32 This effect is also visible in the transient assay applied here (data not shown). However, despite the high constitutive NFB level LMP1 was able to activate NFB about threefold when measured by NFB-dependent reporter gene assay (data not shown). In order to evaluate whether LMP1 activates other cellular genes in L428 cells known to be regulated by NFB, LMP1 or empty vector was transfected into L428 cells. For comparison, different BL cells were investigated. To demonstrate the specificity of LMP1 on NFB dependent surface antigens, effects of the second EBV-encoded latent membrane proteine (LMP2) were also investigated. Cells were enriched after transfec- tion and analyzed for surface antigen expression. The data are mean values ± s.e.m. obtained from at least five independent experiments. As summarized in Table 2 , LMP1 activates Fas, CD40 and CD54 gene expression in L428 cells as well as in BL41 and BL2 cells. Activation of the IL-2 R ␥-chain was observed in L428 cells and in BL2 cells, but not in BL41 cells. LMP2 was unable to promote an activation of these surface antigens in L428 cells.
LMP1-mediated activation of CD25 surface expression is associated with enhanced shedding of the soluble variant of CD25
The IL2R ␣-chain exists as a transmembrane molecule on the cell surfaces and as a truncated soluble form (sCD25). sCD25 in the serum has been suggested as a measure of Genes and Immunity CD25-expressing malignancies. 35, 36 In order to determine whether CD25 activation in LMP1 expressing cells is associated with enhanced sCD25 a specific ELISA was performed. sCD25 expression was analyzed in supernatants of transfected L428 and BL2 cells 24-h and 48-h after magnetic enrichment. As depicted in Figure 5 basal expression of sCD25 was higher in supernatants of vector control-transfected L428 cells than in supernatants of BL2 cells. Interestingly, in contrast to a higher sCD25 amount in supernatants of L428 cells, BL2 show a higher basal CD25 surface expression than L428 cells (Table 1 ). When measured 48 h after magnetic enrichment 29 pg/ml of sCD25 (mean value) were detected in supernatants of vector control-transfected BL2. In supernatants of L248 cells 140 pg/ml of sCD25 (mean value) was found 48 h after MACS. As described above, LMP1 expression led to an enhanced CD25 expression in BL2 cells as well as in L428 cells (Table 1) . However, sCD25 amount was markedly higher in supernatants of LMP1 expressing L428 cells than in BL2 cells. Forty-eight hours after MACS 363 pg/ml sCD25 were detected in L428 cells, while BL2 cells expressed 59 pg/ml in this soluble variant.
Discussion
EBV infection is associated with phenotypic changes of the infected cells, caused by activation of cellular genes including adhesion molecules like ICAM1/CD54, B cell activation markers such as CD40 and cytokines. 2, 6, 16, 17, 37 The transforming viral protein LMP1 is the major effector of phenotypic changes triggering NFB and JNK/AP1 activities. 6, 7, 11, 16, 17 In this study we report that EBVpositive Burkitt's lymphoma cells show a significantly higher expression of CD25 surface level than their noninfected counterparts. Transient LMP1 expression mediates activation of the CD25 gene in tumour cells of different origin. High CD25 expression by EBV-transformed B cells have been previously reported, but was discussed as a consequence of cloning selection of infected cells in culture. 38, 39 Our study demonstrates that LMP1 directly influences the expression of a gene playing an important role in a number of immunological functions.
CD25, the 55-kDa inducible component of the IL-2R complex is usually expressed by T cells as a consequence of T cell receptor mediated activation, which leads to a high affinity IL-2R consisting of the IL-2R ␣-, ␤-and ␥-chain. 40 In T cells, the CD25 gene is potently induced by antigens, mitogens and by viral proteins like transactivator protein (tax) of HTLV-I. 41 Interestingly, high CD25 surface expression has been described for several hematological malignancies, including hairy cell leukemia (HCL), B-chronic lymphocytic leukemia (B-CLL) and Hodgkin's disease. 27, 39, [42] [43] [44] High CD25 surface expression by malignant B cells led to the speculation that IL-2 may play a role in the pathophysiology of these diseases. However, HD-derived cell lines and some B-CLL cells are all IL-2 negative and do not respond to IL-2 stimulation. 27, 28, 43 We have previously shown that expression of EBV nuclear antigen (EBNA) 1 in the HD cell line L428 enhances CD25 surface level, indicating that various factors may contribute to enhanced CD25 expression in Hodgkin's disease. 28 However, the mechanism and function of enhanced CD25 surface expression are still unclear.
In this study the molecular mechanism of LMP1- Figure 5 LMP1-mediated CD25 activation is associated with enhanced secretion of soluble CD25. BL2 and L428 cells were transfected with the plasmids pSG5, pSG5-LMP1 as described above. Forty-eight hours after magnetic enrichment cell supernatants were harvested, the sCD25 content was measured by ELISA. mediated CD25 gene regulation was analyzed. Investigation of functional LMP1 regions showed that the Cterminal activating region 2 had a significantly higher activation capacity than CTAR1, suggesting that NFB activation is necessary and sufficient for CD25 gene regulation. In agreement with this finding constitutive repressive IB-␣ was able to inhibit LMP1-mediated CD25 activation nearly completely in BL2 cells. Furthermore, these results are in line with studies on CD25 gene regulation in T cells. 26, 45, 46 The ability of LMP1 to activate CD25 expression demonstrates again the functional similarities between LMP1 and CD40 signalling reported by several groups. 16, 19, 47, 48 Whether CD25 surface expression of H-RS cells is associated with EBV infection of Hodgkin's disease lesions is not clear. Herbst and coworkers 49 did not find any correlation between EBV and enhanced CD25 surface expression in primary HD tissues. However, CD25 not only exists as a membrane-bound form but also as soluble variant. As reported in this study LMP1 expression in L428 HD cells was associated with enhanced CD25 surface expression and the soluble form. Thus, it could not be ruled out that shedding of surface CD25 also takes place in lesions from HD patients. In patients with Bsymptoms the levels of sCD25 were significantly higher than in patients without B-symptoms. 50 IL-2R ␣-, ␤-and ␥-chains are regularly expressed on HD cell lines and primary H-RS cells. As these cells are not producing IL-2 it could be that either H-RS cells are stimulated by IL-2 produced by bystander T cells or sCD25 could serve as an immunosuppressor in binding the IL-2 necessary for T cell activation. 35 Burton and coworkers 51 hypothesized that the presence of an expanding mass of malignant B cells possessing high and low affinity membrane IL-2R may contribute significantly to the associated immunodeficiency seen in B-CLLs. However, more recent data suggest that CD25 on one cell can present IL-2 to IL-2R ␤-and ␥-chains on another cell to augment IL-2 signalling. This suggests an intercellular augmentation of cytokine effects which may be important for the pathogenesis of malignancies. 52 Considerable evidence has accumulated supporting a critical role of defined subsets of T cells in the control of EBV infection and transformation. 53 Because IL-2 and thus the soluble CD25 can modulate T cell immunity it could be proposed to play an important role in regulating EBV infection. Since there is relevant interest in the application of cellular therapies with EBVimmune T cells for prevention or treatment of lymphomas, the potential of EBV and in particular LMP1 to modulate the expression of the IL-2 receptor ␣-chain (CD25) has to be taken into account when developing new therapeutic strategies.
Materials and methods

Cell lines
L428 is a cell line established from a patient with Hodgkin's disease. BL2, BL30, BL41, BL2-B95-8, BL30-B95-8 and BL41-B95-8 are Burkitt's lymphoma cell lines (kindly provided by M Falk and G Lenoir). Cells were maintained in RPMI 1640 supplemented with 10% fetal calf serum (FCS) and glutamine; penicilline; streptomycine at cell densities between 2 × 10 5 and 1 × 10 6 cells per ml.
Plasmid constructs
Recombinant derivatives of the LMP1 expression vector pSG5 (Stratagene, CA, USA) containing the open-reading frames for LMP1 and FLAG-LMP1 mutants were kindly provided by E Kieff or cloned as follows: 9 To generate FLAG tagged LMP1 mutants, FLAG tagged LMP1 was recloned as BamHI fragment into pbluescript KSII (Stratagene). LMP1 mutants used in these experiments were generated by PCR using the following oligonuceotide primers: oligonucleotide 5Ј GATGAACACCACCAC GATGACTCCCTCCCGCACGCCCAACAAGCTGCCGA TGATTCTGG CCATGAATCTGAC 3Ј creates a non-functional CTAR1 by substition of amino acids 204 and 208. Oligonucleotide 5Ј GAGCGTCTAGAGGATCCTTAGTC GGGGGCGGCGCTTAGCTGAACTGGGCCGTGGGGGT C 3Ј mutates CTAR2 by disturbing the TRADD binding site. Mutated LMP1 fragments were cloned as Bg1II-Xba fragment into pbluescript-FLAG-LMP1, recloned as BamHI fragment into pSG5 and analyzed by sequencing. pMACS4.1 was obtained from Miltenyi Biotec (Bergisch Gladbach, Germany).
Transfection and MACS-enrichment of transfected cells
For transient LMP1 expression assays cells were transfected with 10 g pMACS4.1 (Miltenyi Biotech) and 10 g of the corresponding expression vector pSG5 or pSG5-LMP1 or pSG-FLAG-LMP1 derivatives. All cells were transfected by electroporation as described previously. 9 After electroporation cells were grown for 24-48 h in RPMI 1640, supplemented with glutamine; penicilline; streptomycine, 10 mM HEPES pH 7.5 and 10% FCS. Transfected cells were enriched by a CD4-specific MACS and seeded out at a cell density of 3 × 10 5 cells per ml. Purity of enriched cells was determined by FACS using ␣-CD4-PE antibody. 9, 28 Cells were cultured for 3-5 days for further analysis. Supernatants, cells for Western blot analysis and flow cytometry analysis were harvested every 24 h after MACS.
Western blot analysis
For Western blot analysis cells were harvested and washed with PBS. Cellular extracts were prepared in Laemmli buffer, boiled for 10 min and chilled on ice. Proteins were separated on a discontinuous SDS-PAGE with a 10-12.5% acrylamide resolving gel before electroblotting onto nitrocellulose filters (Hybond C extra; Amersham-Pharmacia Biotech, Freiburg, Germany). Equal loading of the gels was verified by Ponceau S staining. Expression of the proteins was analyzed using the following antibodies: monoclonal mouse ␣-LMP1 (CS.1-4; Dako, Clostrup, Denmark).
Specifically bound antibodies were detected using peroxidase (HRP) coupled secondary goat ␣-mouseantibody (Dako), and visualized by enhanced chemoluminescence (Amersham-Pharmacia Biotech). The luminescence reaction was visualized by exposure to KodakBioMax (Sigma-Aldrich, Deisenhoven, Germany).
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Immunofluorescence analysis
For detection of cell-surface antigen expression, 1 × 10 6 cells were washed twice in PBS supplemented with 0.5% bovine serum albumin (BSA). For immunofluorescence staining cells were incubated with fluorescein (FITC) or phycoerythrin (PE) conjugated monoclonal antibodies for 10 min on ice. After washing twice with PBS (0.5%BSA), cells were resuspended in PBS (0.5% BSA). Flow cytometry was performed using a FACS-Calibur (BD, San Jose, CA, USA). Data are presented as specific mean linear fluorescence intensity after substraction of background staining with isotype-matched control. Dead cells were excluded by propidium-iodide staining. Monoclonal antibodies used, and their sources were as follows: IgG1 FITC/PE, CD25-PE, CD40-FITC, CD95-FITC, IL-2R ␤-chain-PE (CD122), ␥-chain-PE (BD), CD30-FITC, CD4-PE (Immunotech, France), CD54-FITC (Diaclone, Besancon, France).
sCD25-ELISA
Transfected cells were cultured after MACS enrichment for 24 h and longer in RPMI 1640 complete medium. sCD25 content of the supernatants was measured by sCD25 specific ELISA assay (Diaclone). The detection limit of the sCD25-ELISA was 8 pg/ml.
Statistical analysis
Results are presented as mean ± s.e.m. Statistical significance was calculated by the Wilcoxon/Kruskal-Wallis test (non-paired) using JMP program. Statistical significance was accepted for P Ͻ 0.05.
